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Evidence suggests that endothelial dysfunction is on the causal pathway for both atherogenesis and destabilization of
established plaques. In this review, the role of flow-mediated dilatation (FMD) as a non-invasive method to assess
endothelial function is discussed. Technical modifications and development of analysis software have significantly
improved the variability of the method. Following a strict standardized protocol enables reproducible measurements
to be achieved and export of the technique from specialized laboratories to population studies and multicentre set-
tings. Endothelial function assessed by FMD has been shown to be affected by cardiovascular risk factors, to be
related to structural arterial disease and to cardiovascular outcome, validating its use for studying the pathophysiology
of arterial disease. Numerous studies have also demonstrated that it is responsive to physiological and pharmacologi-
cal interventions. Flow-mediated dilatation provides unique opportunities in drug development programmes to assess
an early rapidly responsive signal of risk or benefit, complementing endpoints of structural arterial disease and car-
diovascular outcomes that take much longer and are more expensive.
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Introduction
Advances in the understanding of the vascular biology of athero-
sclerosis have revolutionized the clinical approach to its manage-
ment. It is now clear that vascular disease begins in childhood
and progresses silently for many years until its late clinical manifes-
tations, which include myocardial infarction and stroke, occur.
Dynamic changes in vascular biology characterize both the early
pre-clinical phase and established atherosclerosis, and the vascular
endothelium plays a key role in this process.1 The latter is opti-
mally situated to act as a signal transducer between the circulation
and the vessel wall and produces a wide range of factors that
regulate vessel tone, cell adhesiveness, vascular growth, and coagu-
lation.2 Alterations in endothelial function precede the develop-
ment of morphological changes and contribute to atherosclerotic
lesion development and progression.3–6 These disturbances in
endothelial function also participate in the inflammatory changes
in the atherosclerotic artery, which destabilize established
plaques to increase the risk of clinical events.1
Appreciation of the role of the vascular endothelium through-
out the atherosclerotic disease process has led to the develop-
ment of a range of invasive and non-invasive techniques which
permit evaluation of different aspects of its function.7 These
methods have provided insights into the pathophysiology of
atherosclerosis. They have also provided opportunities to
study the impact of interventions on endothelial function and
add greatly to objective assessment of response to treatments
in clinical trials.
The present review examines the role of flow-mediated dilata-
tion (FMD), which is the most widely used non-invasive ultrasound
method to assess endothelial function. The evolution of the tech-
nique to provide accurate and reproducible data is described
together with its value and limitations in clinical practice and its
role in drug development programmes.
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Clinical study of
endothelial-dependent dilatation
The importance of the vascular endothelium in regulating vascular
homoeostasis was first recognized by its effect on vascular tone.
Pioneering experimental work, in the 1980s, using isolated blood
vessels, demonstrated that stimulation of rabbit aorta with acetyl-
choline resulted in relaxation that was dependent on the presence
of an intact endothelium.8 This endothelium-dependent relaxation
was shown to be mediated by nitric oxide (NO).8
Nitric oxide has numerous functions in the maintenance of
arterial wall homoeostasis, which are lost when the endothelium
becomes dysfunctional. In clinical practice, the impact of NO bioa-
vailability on vasomotion is most commonly studied and evidence
suggests that it represents a barometer of other key functions of
the endothelium. In 1986, the experimental observations of Furch-
gott were adapted for the study of endothelial function in patients
undergoing cardiac catheterization.9 Infusion of acetylcholine in
patients with coronary artery disease resulted in paradoxical vaso-
constriction, whereas dose-dependent dilatation was observed in
patients with ‘smooth’ coronary arteries. Other pharmacological
agents can produce similar effects, as can an increase in flow
induced by distal infusion of vasodilators such as adenosine and
papaverine. In 1992, we reported a new method to perform the
same experiment of FMD non-invasively in conduit arteries in
the peripheral circulation.10 An increase in flow was induced by
inflation and subsequent release of a sphygmomanometer cuff on
the distal forearm and the impact of this ‘physiological’ stimulus
on artery diameter above the elbow was assessed by high-
resolution ultrasound. The FMD in the brachial and radial arteries
is almost completely abolished by inhibitors of eNOS demonstrat-
ing its dependence on local NO bioavailability.11 Many studies have
subsequently shown impairment of FMD in response to a range of
cardiovascular (CV) risk factors and its recovery after treatment.
Anderson et al.12 were the first to report a relationship between
endothelial-dependent vasodilatation in the brachial and the cor-
onary circulation using pharmacological agents in the coronary
experiments and flow as a stimulus in the peripheral circulation.
The coexistence of endothelial dysfunction in the coronary and
brachial arteries was confirmed by Takase et al.13 using flow as a
stimulus in both vascular beds with a high correlation. This suggests
that endothelial function varies throughout the vasculature and, in
conjunction with local haemodynamics and other factors, deter-
mines the development and progression of focal atherosclerosis.
The measurement of endothelial function in the conduit arteries
of the peripheral circulation by FMD enables study of the key
aspects of vascular biology in pre-clinical subjects in whom invasive
testing is not feasible.7
Flow-mediated dilatation
methodology
While the concept of FMD is simple, measurement is challenging
and involves systematic training to reach the plateau of the learning
curve for both image acquisition and image analysis.14 Over the last
20 years, technical modifications and the development of analysis
software have greatly improved image acquisition and reduced
method variability.
Subject preparation
A number of patient related and environmental factors have been
shown to influence FMD, including mental stress, food, drugs, and
temperature.15,16 Current guidelines recommend that subjects
should have FMD measurement in a fasting state (8–12 h) and
be studied in a quiet, temperature-controlled room.14,17 Tobacco
use should be avoided for at least 4–6 h before the study
and, for female individuals, the phase of the menstrual cycle
should be reported, since hormonal changes may affect FMD
results.18,19 Recent data, however, from population studies,
demonstrate that the contribution of environmental factors to
the variability of FMD is relatively small, and these should not be
considered limiting factors for FMD assessment when the ‘ideal’
conditions cannot be achieved.20
Image acquisition and site selection
Before initiating an FMD study, the subject should rest for
.10 min to ensure stable conditions during scanning.21 In most
cases, the brachial artery is the preferred site of measurement
(usual diameter 2.5–5 mm). In pre-pubertal children, the femoral
artery can be also studied, but is too large in older subjects.
Arteries with smaller diameter are difficult to image accurately
and reproducibly and very small changes in absolute diameter
are consequently reported as large percentage changes. Longitudi-
nal images of the brachial artery are obtained with a high-
resolution ultrasound probe (usually 7–12 MHz), while the
subject lies in supine position with the arm resting in a comfortable
position in a cradle support. The interface between the near and
far arterial wall and the vessel lumen has to be clearly defined. Bra-
chial diameter measurements are obtained in end-diastole, ident-
ified by the onset of the R-wave.14 This period is preferred since
functional characteristics of the artery such as vessel compliance,
which influence the extent of systolic expansion, are unlikely to
interfere with diameter measurements.14 Finally, anatomical land-
marks have to be identified and the use of a stereotactic adjustable
probe-holding device is necessary to ensure that image quality and
plane are maintained throughout the study (Figure 1). To ensure
that the examiner will be able to restudy the original position of
the brachial artery when the subject is re-examined it is important
that the positions of the arm, hand, and head are noted, along with
the distance between the pneumatic cuff and the probe during the
first examination. It is also helpful to make a thermal print of the
arterial image for matching at subsequent visits.22
Sphygmomanometer probe position
In the original description for brachial FMD measurement, the
sphygmomanometer blood pressure cuff was placed on the
forearm, and the brachial artery was imaged above the antecubital
fossa. This remains the technique of choice, with placement of the
cuff 1–2 cm distal to the elbow crease. Placement of the cuff more
distally around the wrist results in lower reactive hyperaemia and
lower FMD.23 Placement of the occlusion cuff above the imaging
probe has also been advocated.24 Proximal cuff positioning may
affect the magnitude and peak vasodilatory response and also
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the time course of the peak response.23 Although this has been
advocated to enable the differentiation of subtle differences in an
FMD response between different groups, there are major concerns
about the validity of this approach. Imaging is challenging as the
artery can collapse or distort during cuff inflation and the
measured vasodilatation obtained with a proximal cuff placement
is confounded by ischaemic mediators other than NO, making
this approach inapplicable for studies where NO bioavailability is
the focus of interest.24 (Figure 1).
Cuff occlusion time
The original cuff occlusion duration of 5 min has stood the test of
time. Subsequent studies have shown that cuff occlusion of
,1.5 min is not followed by significant dilatation, whereas FMD
increases linearly with increasing cuff occlusion times of up to
4.5 min.16 However, no further increase in maximal dilator
response is seen when the cuff occlusion time is extended
further to 10 min.16 The cuff is inflated to ≥50 mmHg above sys-
tolic pressure to occlude arterial inflow and this causes ischaemia
and subsequent dilatation of downstream resistance vessels by
autoregulatory mechanisms. On cuff deflation, reactive hyperaemia
in the brachial artery occurs and results in vasodilatation if endo-
thelial function is intact.25
Flow-mediated dilatation analysis
A number of studies have demonstrated that maximal increase in
diameter occurs 45–60 s after the release of the cuff. New semi-
automatic measurement software is now available and this permits
faster, less subjective and more reproducible measurement of the
arterial diameter compared with previously used manual measure-
ment.22 Additionally, analysis software can characterize the whole
profile of change in brachial artery diameter. It has been suggested
that measurement of vasoconstriction, which can occur during cuff
inflation may provide additional information on endothelial func-
tion and can complement FMD.26
Characterization of the flow-mediated
dilatation response
Flow-mediated dilatation is commonly reported as percentage
change from the baseline diameter. Other parameters such as
FMD at 60 s, area under the response curve and time to peak
have also been used to describe the dilatory response.22
However, recent data show that per cent maximum FMD is the
most reproducible measure and the best discriminator between
health and disease.22 The influence of baseline diameter on FMD
is important. Vessel size influences an FMD response, both by an
impact on blood flow-related shear stress on the vessel wall, and
also by being part of the calculation of percentage FMD. Absolute
change in FMD (millimetre) is unrelated to resting vessel size. Per-
centage FMD is currently recommended, for interventional and
longitudinal studies in which baseline vessel diameter remains
stable over time.22 However, measurement and reporting of the
baseline diameter, absolute change and percentage FMD in diam-
eter are advisable. Equally important is the characterization of
the hyperaemic stimulus for serial measurements and comparisons
between groups.
Figure 1 Set up for flow-mediated dilatation. (A) Recommended positioning of the sphygmomanometer cuff and use of the ultrasound probe
holder. (B) Placement of the region of interest box using the edge detection analysis software for flow-mediated dilatation analysis. (C) Output
generated by edge detection software that permits assessment of the vasodilatory response.
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Accuracy and reproducibly of
flow-mediated dilatation measurement
Studies of FMD have been performed with widely varying adher-
ence to the key methodological issues outlined above. Reproduci-
ble FMD measurements, as with other imaging modalities, require
careful attention to training, technique, and analysis. We have
recently reported sources of variability from a single experienced
centre.22 This has shown the feasibility of using FMD as an end-
point in serial studies and interventional trials. Power curves
have been published to assist in the design of both crossover
and parallel trials22 (Figure 2) and a nomogram of FMD values is
available for use as a reference for various vessel sizes (Figure 3).22
Pathophysiology of endothelial
dysfunction
The healthy endothelium plays an important role in the mainten-
ance of arterial homoeostasis. Many of its functions are regulated
by the bioavailability of the NO, including inflammation, adhesion,
coagulation, smooth muscle cell proliferation, and vasomotion. In
response to a range of triggers, endothelial dysfunction leads to
a switch from a NO to a reactive oxygen species (ROS)-dominated
inflammatory environment.1 Flow-mediated dilatation measures
the vasomotor consequences of this change in arterial wall pheno-
type and can therefore be used to study the vascular biology of
atherosclerosis as it evolves from childhood.27
Relation to cardiovascular risk factors
Flow-mediated dilatation has been shown to be adversely affected
by classical CV risk factors. Gradual deterioration of FMD has been
reported with ageing, and increased oxidative stress has been
Figure 2 Power curves for estimating subjects required for flow-mediated dilatation studies in crossover and parallel studies. Relation
between effect on maximum percent change in flow-mediated dilation (%) and number of subjects required in crossover and parallel study
designs at 80% power and 5% significance, 4–6 h and 3 months apart with three monitoring strategies: 1, 2, or 4 measures pre- and
post-treatment.
Figure 3 Nomogram for flow-mediated dilatation according to
the vessel baseline diameter. A negative linear association exists
between baseline diameter and flow-mediated dilatation. For a
specific baseline diameter, flow-mediated dilatation can be esti-
mated. The black line shows the 75th percentile, the circle
dashed line the 50th percentile, and the rectangular dashed line
the 25th percentile of the population.
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suggested as the responsible mechanism.28 The adverse effect of
cholesterol on endothelial function was first reported in children
with familial hypercholesterolaemia (FH) from as early as 8 years
of age.29 In this study, the degree of endothelial impairment
correlated with both LDL and Lp(a) levels.29 In non-genetic dysli-
pidaemias, increased cholesterol is associated with endothelial dys-
function, but the degree of impairment is relatively weak. Oxidized
LDL has been identified as an important mediator of endothelial
damage and subjects with a higher proportion of small dense
LDL particles may have endothelial dysfunction, irrespective of
total or LDL plasma concentrations.30–32 There is increasing inter-
est in the role of HDL in the vascular biology of atherosclerosis.
Recombinant HDL infusions have been shown to improve FMD
and recent evidence suggests that the composition and function
of HDL may have an important effect on the endothelium, in
addition to plasma levels.33,34 Less information is available for the
impact of hypertriglyceridaemia on endothelial function. Although
lower FMD has been reported in young men with hypertriglycer-
idaemia, acute administration of triglycerides to normal individuals
has not been shown to affect endothelial function.35,36 Dietary
studies involving fat loads have shown variable acute responses
of FMD, which may reflect differences in fat composition.37,38
Diabetic patients demonstrate impaired endothelial function
responses.39 Potential mechanisms for the reduced NO bioavail-
ability include the formation of ROS, activation of protein kinase
C, decreased NO synthase expression, formation of advanced
glycosylation end products and reduction in intracellular
NADP.40,41 There are few studies of chronic endothelial function
in type 1 diabetes.42 In young individuals, FMD impairment was
related to duration of diabetes and LDL levels.39 In other
studies, the coexistence of microalbuminuria has been shown to
have significant impact on endothelium-dependent responses.43
In addition, high-glucose levels after acute loading has been
associated with impaired endothelial function in some clinical
studies but not all.44,45
Blunted FMD responses have also been reported in subjects
with hypertension and correlate with severity and duration of
blood pressure elevation.46,47 Nevertheless, the pathogenesis of
the association between endothelial dysfunction and hypertension
remains unclear. A number of studies have suggested that in hyper-
tensive subjects, increased levels of potent vasoconstrictors such
as angiotensin II and endothelin-1 promote endothelial dysfunction.
In others, endothelial dysfunction is regarded as the primary event
causing arterial hypertension.48,49 Of interest, endothelial dysfunc-
tion has also been observed in children with secondary hyperten-
sion from renal disease.50
Active and passive cigarette smoking have been shown to have a
deleterious effect on FMD in a dose-dependent manner.51 In a
recent study, the acute impairment in endothelial function after
the use of cigarettes, nicotine spray, and snuff are related to nic-
otine levels.52,53 Nevertheless chronic endothelial dysfunction
may result from a number of additional mechanisms including
inflammation, increased oxidative stress, platelet activation, sym-
pathetic tone, increased asymmetric dimethylarginine (ADMA)
levels, and direct toxic effects of smoke components on endo-
thelial cells.54–56 Impairment in FMD in pre-clinical subjects is
related to the number of risk factors present. This mirrors the
known adverse impact of multiple co-existing risk factors on CV
outcome. This, together with the relation of FMD to structural
disease evolution and outcome (see below), supports the view
that FMD is on the causal pathway for atherogenesis.
It is increasingly recognized that metabolic abnormalities sec-
ondary to obesity play an important role in the development of
arterial disease. Endothelial dysfunction can be demonstrated in
obese subjects from teenage years and is associated with visceral
fat deposition. Flow-mediated dilatation can also be used to
describe novel pathophysiological pathways involved in athero-
sclerosis. For example, Jarvisalo et al.57 demonstrated the presence
of endothelial dysfunction in adult men who were formula fed from
infancy. Hingorani et al.58 showed that brief exposure to a systemic
inflammatory stimulus, typhoid vaccination, induced transient
impairment in FMD. Similar findings have been found for childhood
infection.59 Unexpected sources of chronic inflammation such as
periodontal disease are also associated with endothelial dysfunc-
tion.60 In a randomized clinical trial, this was aggravated by acute
inflammation associated with dental treatment but subsequently
improved steadily as gum disease resolved.
Utility of flow-mediated dilatation
It is increasingly clear that the process of atherosclerosis begins
many years before the clinical events so that there are opportu-
nities for early intervention to alter the progression of disease
and outcome. These require objective measures which can be
used in clinical research to study arterial phenotype and the
response to treatments. Cardiovascular outcome depends on
both the burden of atherosclerosis and its ‘functional state’. Endo-
thelium is a key signal transducer of the inflammatory process,
which may progress structural disease and destabilize established
plaques causing clinical events. There has been considerable inter-
est in the measurement of FMD both in pre-clinical subjects and in
those with established vascular disease.27,30,61 The value of FMD as
an intermediated phenotype and as an outcome measure in trials is
based on its relationship with CV risk factors (see above), with
progression of arterial disease and adverse prognosis.4,30,62
Evidence that endothelial function is on the causal pathway for
atherogenesis comes from a number of sources. Conduit artery
endothelial dysfunction has been demonstrated in young children
with monogenic disorders such as FH which are known to be
associated with pre-mature atherosclerosis and clinical
events.10,63 Furthermore, endothelial function measures are
linked to early structural arterial disease. Juonala et al.3 described
an inverse correlation between brachial artery endothelial function
and carotid intima media thickness (CIMT) in a large cohort of sub-
jects selected from the Cardiovascular Risk in Young Fins Study.
Notably, the preservation of normal vascular function in this
report was associated with an apparent protection from develop-
ing structural arterial disease, as defined by an increased CIMT.3 In
another prospective study of middle aged civil servants (the
Whitehall cohort), FMD was measured at two time points separ-
ated by an observation period of 6.2 years.4 Brachial FMD was
the best predictor of the rate of progression of CIMT and was
superior to Framingham risk score.4 The link between FMD and
structural measures of arterial disease as well as its relationship
to later CV events supports the use of FMD to follow the
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evolution of arterial disease both cross-sectionally and in large
populations throughout its natural history.61,64 Relationships with
risk factors and treatment responses can be defined at a stage of
disease when the atherosclerotic process is likely to be more
amenable to intervention (see below).
The relationship between FMD and CV events has been studied
in different populations, usually with higher CV risk levels.64
Several, but not all, trials have shown incremental prognostic infor-
mation from measurement of FMD in cohorts with established CV
disease (Table 1). In the Cardiovascular Health Study, after adjust-
ment for multiple CV risk factors, FMD remained an independent
and significant predictor for a composite endpoint that included
CV death, myocardial infarction, stroke, congestive heart failure,
intermittent claudication, percutaneous intervention, and cardiac
bypass graft surgery.65 Similar findings were reported in the
Multi Ethnic Study of Atherosclerosis (MESA).66
Response to intervention
Measurement of FMD is non-invasive, repeatable, cheap, and easy
to perform and thus attractive for use in determining both benefits
and potential harm from CV interventions.
Life style modification approaches such as dietary interventions
and exercise have revealed a moderate short-term improvement in
FMD in both children and adults who achieve a stable reduction in
body weight.67,68 Rapid improvements in endothelial function have
also been described after bariatric surgery.69,70 There is evidence
that regular aerobic exercise improves endothelial function and
that benefit is not limited to obese individuals. In the individual
patient, however, the use of FMD to stratify risk and to follow clini-
cal progress is limited by difficulties in standardizing techniques in
clinical practice (see above) and by its intrinsic biological variability.
An increasing challenge is to prioritize drug targets and novel
agents and to develop them for clinical use. Improvement in CV
outcomes has been the requirement for approval of new treat-
ments by regulatory bodies. However, the demonstration of
benefit on CV morbidity and mortality requires very large, expens-
ive trials that involve exposure of numerous subjects to potentially
toxic novel agents. Most importantly, outcome measures are an
inappropriate endpoint for assessment of treatments, which aim
to target the evolution of pre-clinical disease from a young age.
There has, therefore, been great interest in the use of surrogate
outcome measures of arterial structure and function, which are
‘intermittent phenotypes’ on the pathway to clinical atherosclero-
sis and its complications. Flow-mediated dilatation is affected by
CV risk factors and improves in response to drugs that have
proved benefit on CV outcomes such as statins, anti-hypertensive
drugs (including ACE-Inhibitors, angiotensin I receptor blockers,
and calcium channel blockers)71–73 (Table 2). Clinical trials indicate
that beneficial effects on endothelial function may not merely be
attributable to LDL or blood pressure lowering.74–76 Anti-platelet
regimes such as aspirin, clopidogrel, and glycoprotein IIbIIIa inhibi-
tors have been shown to have anti-inflammatory and antioxidant
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Table 1 Flow-mediated dilatation and prognostic information
Study Population Follow-up Conclusions Limitations
Neunteufl
et al.84
Seventy-three patients with CAD,
chronic congestive heart failure
or valvular defects requiring
angiography
5 years No independent prognostic importance of
FMD
Low number of patients
Gokce
et al.85
One hundred and ninety-nine
patients with peripheral arterial
disease before vascular surgery
1.2 years FMD independently predicts long-term
cardiovascular events
Only patients with already established
atherosclerotic disease
Huang
et al.86
Two hundred and sixty-seven
patients with peripheral vascular
disease referred for surgery
10 months FMD predicts cardiovascular events Only patients with already established
atherosclerotic disease
Brevetti
et al.87
One hundred and thirty-one
patients with peripheral vascular
disease
23 months FMD is an independent predictor of events Only patients with already established
atherosclerotic disease
Modena
et al.88
Four hundred post-menopausal and
hypertensive women
67 months After 6 months of anti-hypertensive
treatment subjects without
improvement of endothelial function
identify a group with increased event
rate
Only post-menopausal women with
endothelial dysfunction at baseline
evaluated without any other imaging
tests
Chan et al.89 One hundred and fifty-two
coronary patients
34 months FMD is the dominant, independent
predictor of cardiovascular outcome
Only patients with coronary artery
disease
Fathi et al.90 Four hundred and forty-four
patients deemed at risk of
coronary artery disease
24 months FMD is not an independent predictor of
the cardiovascular outcome
Inclusion of a heterogenic population
with several and serious diseases
(renal dysfunction, diabetes,
advanced coronary diseases)
Hu et al.91 Two hundred and seventy-nine
patients admitted for coronary
angiography due to chest pain
16 months Brachial FMD is an independent predictor
for cardiovascular events
Only patients with chest pain studied
before the angiographic evaluation
CAD, coronary artery disease.
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Table 2 Recent randomized controlled studies and flow-mediated dilatation
Study Population Drug/Follow-up Type of study Outcome
Flammer et al.92 Thirteen patients with type 2 diabetes
mellitus and hypertension
Losartan vs. atenolol, 4 weeks Randomized, double blind,
Crossover study
Losartan improves endothelial function in type 2 diabetic
patients with hypertension compared with atenolol
Koh et al.93 Thirty-four hypertensive patients Ramipril and candesartan, 4 months Randomized, double-blind,
placebo-controlled
crossover trial
Ramipril in combination with candesartan improves blood
pressure, endothelial function and adipocytokine profiles
Flammer et al.94 Eleven patients with rheumatoid arthritis Ramipril, 8 weeks Randomized, double-blind,
crossover study
Ramipril for 8 weeks markedly improved endothelial
function
Morimoto et al.95 Fifty patients with untreated essential
hypertension
Amlodipine vs. Clinidipine, 24 weeks Rondomized trial No differences in the vascular function between two drugs
Hamilton et al.96 Twenty-three statin-treated type 2 diabetic
patients
Oral CoQ(10) vs. placebo, 12 weeks Double-blind, crossover study CoQ(10) supplementation improved endothelial dysfunction
in statin-treated type 2 diabetic patients
Rawlings et al.97 Thirty men with stable atherosclerosis Atorvastatin, rosuvastatin, 28 days Randomized, double-blind
study
Statins improved FMD
Ostad et al.98 Fifty-eight patients with CAD, LDL
cholesterol of .100 mg/dL and
endothelial dysfunction of the brachial
artery
Atorvastatin (80 mg) vs.
Atorvastatin + ezetimibe, 8 weeks
Double-blind trial LDL cholesterol-independent effects of high-dose
atorvastatin therapy account for the improvement of
endothelium-dependent vasodilation in patients with
stable CAD
Settergren et al.99 Thirty-nine patients with type 2 diabetes or
IGT and stable CAD
Simvastatin and ezetimibe/simvastatin
placebo or ezetimibe/simvastatin
and simvastatin placebo, 6 weeks
Randomized, double-blind,
controlled clinical trial
Lipid lowering is more important than pleiotropic effects of
statins for an improvement in endothelial function and
inflammatory markers
Koh et al.100 Thirty-two hypercholesterolaemic patients Simvastatin, 2 month Randomized, double-blind,
placebo-controlled, parallel
study
Simvastatin significantly improved endothelium-dependent
dilation
Ma¨ki-Peta¨ja¨ et al.101 Twenty patients with rheumatoid arthritis Simvastatin or ezetimibe, 6 weeks Randomized, double-blind,
crossover study
Improvement in endothelial function
Vlachopoulos et al.102 Fifty patients with mild
hypercholesterolaemia
Atorvastatin vs. placebo, 4 days of
preconditioning
Randomized, placebo
controlled, double-blind
study
Atorvastatin effectively abrogates the endothelial
dysfunction in hypercholesterolaemic patients treated
with typhoid vaccination
IGT, impaired glucose tolerance; CAD, coronary artery disease.
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actions and their administration has been associated with improve-
ment in endothelial function.77–79 It is important, however, to
appreciate that responses in FMD reflect changes in endothelial
function, which are clearly only one factor influencing CV risk.
While most factors, which improve endothelial function, have
been shown to be of CV benefit, exceptions include antioxidant
supplementation and hormone replacement therapies.80–82 The
lack of outcome benefit in trials may be due to numerous
reasons including dosing, duration of therapy, stage of disease,
potential side effects of therapies, and co-morbidities.
Trials which evaluate FMD need to be part of a portfolio exam-
ining the impact of treatment on arterial function, structure, and
clinical events. An important advantage of FMD as a trial endpoint
is the rapid change in FMD, which occurs as a result of treatment,
so that an objective measure of the impact of a novel drug can be
obtained in a much shorter time (a few months) than required for
a trial with CIMT or outcome endpoints. Use of FMD in this setting
requires standardization of technique, reporting, and analysis.
Considerable progress has been made in all of these areas. In an
analysis from a single expert centre using optimal acquisition meth-
odology and automated analysis software, low levels of variability
were reported and power curves were generated to inform on
clinical trial design.22 This approach has subsequently been
applied successfully to a multinational, multi-centre randomized
clinical trial of the cholestylester transferoprotein (CETP) inhibitor,
dalcetrapib.
Another important opportunity for use of FMD, early in drug
development programmes is the ability to identify not only
benefit but also potential adverse effects on the vessel wall. A
major recent disappointment has been the results of the ILLUMI-
NATE trial, which demonstrated an increase in CV events follow-
ing administration of torcetrapib, despite a substantial rise in HDL
cholesterol.83 This has been attributed to ‘off target’ toxicity and it
is tempting to speculate that an adverse signal might have been
picked up earlier by the study of the effect of torcetrapib on endo-
thelial function. Flow-mediated dilatation trials may thus play an
important role in ‘de-risking’ studies of new agents. Demonstration
of lack of adverse vascular effects or even vascular benefit
increases confidence in the use of such treatments in large-scale
clinical trials over years.
Conclusion
Endothelial function is a key aspect of the disturbed vascular
biology throughout the natural history of atherosclerosis. Evidence
suggests that endothelial dysfunction is on the causal pathway for
both disease evolution and destabilization of established plaques.
Flow-mediated dilatation provides a non-invasive, cheap, and
repeatable measure of endothelial function and has been widely
used in pathophysiological studies and in large cohorts for ‘vascular
epidemiology’. Advances in standardization of methodology and
analysis have made it an attractive method for evaluation of inter-
ventions. In drug development programmes, improvement in FMD
may provide an early rapid signal of both benefit, and the absence
of vascular toxicity and complement trials with endpoints of struc-
tural arterial disease and CV outcomes that take much longer and
are more expensive.
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